Josiah Yarbrough
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Josiah Yarbrough has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Stacey F. Bent
Department of Chemical Engineering, Stanford University, Stanford, USA
5 shared publications - Ralf Tonner
Leipzig University
3 shared publications - Alexander B. Shearer
Department of Chemical Engineering, Stanford University, Stanford, California 94305, United States
2 shared publications Fabian Pieck
Wilhelm Ostwald Institut für Physikalische und Theoretische Chemie, Universität Leipzig, Linnéstr. 2, 04103 Leipzig, Germany
2 shared publicationsPatrick Maue
Wilhelm Ostwald Institut für Physikalische und Theoretische Chemie, Universität Leipzig, Linnéstr. 2, 04103 Leipzig, Germany
2 shared publicationsAlex B. Shearer
Department of Chemical Engineering, Stanford University , Stanford 94305, California
1 shared publication
Latest Publications
- 17 November 2025
- Published by Elsevier in The Journal of Pediatrics
- Vol. 290, 114899
Determination of Highly Resource-Intensive Pediatric Patients: Opportunity for Innovation
- 17 November 2025
- Published by Elsevier in The Journal of Pediatrics
- Vol. 290, 114899
Determination of Highly Resource-Intensive Pediatric Patients: Opportunity for Innovation
- 16 June 2025
- Published by Journal of Science Policy and Governance, Inc. in Journal of Science Policy & Governance
- Vol. 26 (1)
Precision Medicine and the Price of Equity
Medicine has increasingly moved toward more personalized approaches that utilize individual patient characteristics to tailor therapeutic interventions and predict outcomes. While advancements in precision medicine have garnered significant attention, the ways that this budding subset of technology intersects with existing health disparities are often overlooked. Precision medicine holds tremendous potential to transform healthcare, but it risks widening existing disparities if not managed inclusively. We highlight three core issues that further marginalize underserved communities: high costs, limited accessibility of precision medicine, and insufficient diversity in research that produces these innovations. We also propose opportunities for state and federal policymakers to mitigate these issues. Without deliberate policy interventions, these innovations may remain accessible only to privileged demographics, excluding underserved communities from life-saving treatments. Key policy recommendations include restructuring reimbursement frameworks, reducing drug prices, fostering diversity in clinical trials, and building strong community partnerships. These measures are essential to transforming precision medicine from a selective advantage to a universally accessible health benefit.
- 16 June 2025
- Published by Journal of Science Policy and Governance, Inc. in Journal of Science Policy & Governance
- Vol. 26 (1)
Precision Medicine and the Price of Equity
Medicine has increasingly moved toward more personalized approaches that utilize individual patient characteristics to tailor therapeutic interventions and predict outcomes. While advancements in precision medicine have garnered significant attention, the ways that this budding subset of technology intersects with existing health disparities are often overlooked. Precision medicine holds tremendous potential to transform healthcare, but it risks widening existing disparities if not managed inclusively. We highlight three core issues that further marginalize underserved communities: high costs, limited accessibility of precision medicine, and insufficient diversity in research that produces these innovations. We also propose opportunities for state and federal policymakers to mitigate these issues. Without deliberate policy interventions, these innovations may remain accessible only to privileged demographics, excluding underserved communities from life-saving treatments. Key policy recommendations include restructuring reimbursement frameworks, reducing drug prices, fostering diversity in clinical trials, and building strong community partnerships. These measures are essential to transforming precision medicine from a selective advantage to a universally accessible health benefit.
- 18 December 2024
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 37 (1) , 139-152
Role of Molecular Orientation: Comparison of Nitrogenous Aromatic Small Molecule Inhibitors for Area-Selective Atomic Layer Deposition
- 18 December 2024
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 37 (1) , 139-152
Role of Molecular Orientation: Comparison of Nitrogenous Aromatic Small Molecule Inhibitors for Area-Selective Atomic Layer Deposition
- 8 September 2023
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry A
- Vol. 127 (37) , 7858-7868
Area-Selective Deposition by Cyclic Adsorption and Removal of 1-Nitropropane
The ever-greater complexity of modern electronic devices requires a larger chemical toolbox to support their fabrication. Here, we explore the use of 1-nitropropane as a small molecule inhibitor (SMI) for selective atomic layer deposition (ALD) on a combination of SiO2, Cu, CuOx, and Ru substrates. Results using water contact angle goniometry, Auger electron spectroscopy, and infrared spectroscopy show that 1-nitropropane selectively chemisorbs to form a high-quality inhibition layer on Cu and CuOx at an optimized temperature of 100 °C, but not on SiO2 and Ru. When tested against Al2O3 ALD, however, a single pulse of 1-nitropropane is insufficient to block deposition on the Cu surface. Thus, a new multistep process is developed for low-temperature Al2O3 ALD that cycles through exposures of 1-nitropropane, an aluminum metalorganic precursor, and coreactants H2O and O3, allowing the SMI to be sequentially reapplied and etched. Four different Al ALD precursors were investigated: trimethylaluminum (TMA), triethylaluminum (TEA), tris(dimethylamido)aluminum (TDMAA), and dimethylaluminum isopropoxide (DMAI). The resulting area-selective ALD process enables up to 50 cycles of Al2O3 ALD on Ru but not Cu, with 98.7% selectivity using TEA, and up to 70 cycles at 97.4% selectivity using DMAI. This work introduces a new class of SMI for selective ALD at lower temperatures, which could expand selective growth schemes to biological or organic substrates where temperature instability may be a concern.
- 8 September 2023
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry A
- Vol. 127 (37) , 7858-7868
Area-Selective Deposition by Cyclic Adsorption and Removal of 1-Nitropropane
The ever-greater complexity of modern electronic devices requires a larger chemical toolbox to support their fabrication. Here, we explore the use of 1-nitropropane as a small molecule inhibitor (SMI) for selective atomic layer deposition (ALD) on a combination of SiO2, Cu, CuOx, and Ru substrates. Results using water contact angle goniometry, Auger electron spectroscopy, and infrared spectroscopy show that 1-nitropropane selectively chemisorbs to form a high-quality inhibition layer on Cu and CuOx at an optimized temperature of 100 °C, but not on SiO2 and Ru. When tested against Al2O3 ALD, however, a single pulse of 1-nitropropane is insufficient to block deposition on the Cu surface. Thus, a new multistep process is developed for low-temperature Al2O3 ALD that cycles through exposures of 1-nitropropane, an aluminum metalorganic precursor, and coreactants H2O and O3, allowing the SMI to be sequentially reapplied and etched. Four different Al ALD precursors were investigated: trimethylaluminum (TMA), triethylaluminum (TEA), tris(dimethylamido)aluminum (TDMAA), and dimethylaluminum isopropoxide (DMAI). The resulting area-selective ALD process enables up to 50 cycles of Al2O3 ALD on Ru but not Cu, with 98.7% selectivity using TEA, and up to 70 cycles at 97.4% selectivity using DMAI. This work introduces a new class of SMI for selective ALD at lower temperatures, which could expand selective growth schemes to biological or organic substrates where temperature instability may be a concern.
- 19 July 2023
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 35 (15) , 5963-5974
Area-Selective Atomic Layer Deposition of Al2O3 with a Methanesulfonic Acid Inhibitor
- 19 July 2023
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 35 (15) , 5963-5974
Area-Selective Atomic Layer Deposition of Al2O3 with a Methanesulfonic Acid Inhibitor
- 7 October 2022
- Published by Springer Nature in Oncogene
- Vol. 41 (45) , 4960-4970
MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes
MYC is a transcription factor frequently overexpressed in cancer. To determine how MYC drives the neoplastic phenotype, we performed transcriptomic analysis using a panel of MYC-driven autochthonous transgenic mouse models. We found that MYC elicited gene expression changes mostly in a tissue- and lineage-specific manner across B-cell lymphoma, T-cell acute lymphoblastic lymphoma, hepatocellular carcinoma, renal cell carcinoma, and lung adenocarcinoma. However, despite these gene expression changes being mostly tissue-specific, we uncovered a convergence on a common pattern of upregulation of embryonic stem cell gene programs and downregulation of tissue-of-origin gene programs across MYC-driven cancers. These changes are representative of lineage dedifferentiation, that may be facilitated by epigenetic alterations that occur during tumorigenesis. Moreover, while several cellular processes are represented among embryonic stem cell genes, ribosome biogenesis is most specifically associated with MYC expression in human primary cancers. Altogether, MYC’s capability to drive tumorigenesis in diverse tissue types appears to be related to its ability to both drive a core signature of embryonic genes that includes ribosomal biogenesis genes as well as promote tissue and lineage specific dedifferentiation.
- 7 October 2022
- Published by Springer Nature in Oncogene
- Vol. 41 (45) , 4960-4970
MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes
MYC is a transcription factor frequently overexpressed in cancer. To determine how MYC drives the neoplastic phenotype, we performed transcriptomic analysis using a panel of MYC-driven autochthonous transgenic mouse models. We found that MYC elicited gene expression changes mostly in a tissue- and lineage-specific manner across B-cell lymphoma, T-cell acute lymphoblastic lymphoma, hepatocellular carcinoma, renal cell carcinoma, and lung adenocarcinoma. However, despite these gene expression changes being mostly tissue-specific, we uncovered a convergence on a common pattern of upregulation of embryonic stem cell gene programs and downregulation of tissue-of-origin gene programs across MYC-driven cancers. These changes are representative of lineage dedifferentiation, that may be facilitated by epigenetic alterations that occur during tumorigenesis. Moreover, while several cellular processes are represented among embryonic stem cell genes, ribosome biogenesis is most specifically associated with MYC expression in human primary cancers. Altogether, MYC’s capability to drive tumorigenesis in diverse tissue types appears to be related to its ability to both drive a core signature of embryonic genes that includes ribosomal biogenesis genes as well as promote tissue and lineage specific dedifferentiation.
- 10 May 2022
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 34 (10) , 4646-4659
Tuning Molecular Inhibitors and Aluminum Precursors for the Area-Selective Atomic Layer Deposition of Al2O3
- 10 May 2022
- Published by American Chemical Society (ACS) in Chemistry of Materials
- Vol. 34 (10) , 4646-4659
Tuning Molecular Inhibitors and Aluminum Precursors for the Area-Selective Atomic Layer Deposition of Al2O3
- Top Cited Papers
- 1 March 2021
- Published by American Vacuum Society in Journal of Vacuum Science & Technology A
- Vol. 39 (2) , 021002
Next generation nanopatterning using small molecule inhibitors for area-selective atomic layer deposition
Area-selective atomic layer deposition (ALD) is an approach to self-aligned, bottom-up nanofabrication with the potential to overcome many of the challenges facing the semiconductor industry around continued device downscaling. Currently, the most common method for achieving area-selective ALD uses self-assembled monolayers (SAMs) as a means of surface deactivation. Alternative routes are also being pursued that may better meet the demands of high-volume device manufacturing and overcome some disadvantages of the SAM method. One promising alternative is the use of small molecule inhibitors (SMIs). This Perspective provides an overview of the current developments in the use of SMIs for selective deposition by describing systems from the literature and providing insight into SMI selection. Although little is yet known about the mechanistic behavior of SMIs, this Perspective aims to lay the framework for both a better understanding of their inhibitive performance and strategies to innovate their design. It establishes two key interfaces—between the ALD precursor and the inhibitor, and between the inhibitor and the substrate—and discusses the role of each in selective deposition. Building upon the established understanding of SAMs together with current knowledge of SMIs, this Perspective aims to define guiding principles and key considerations for improving SMI design.
- 1 March 2021
- Published by American Vacuum Society in Journal of Vacuum Science & Technology A
- Vol. 39 (2) , 021002
Top Cited PapersNext generation nanopatterning using small molecule inhibitors for area-selective atomic layer deposition
Area-selective atomic layer deposition (ALD) is an approach to self-aligned, bottom-up nanofabrication with the potential to overcome many of the challenges facing the semiconductor industry around continued device downscaling. Currently, the most common method for achieving area-selective ALD uses self-assembled monolayers (SAMs) as a means of surface deactivation. Alternative routes are also being pursued that may better meet the demands of high-volume device manufacturing and overcome some disadvantages of the SAM method. One promising alternative is the use of small molecule inhibitors (SMIs). This Perspective provides an overview of the current developments in the use of SMIs for selective deposition by describing systems from the literature and providing insight into SMI selection. Although little is yet known about the mechanistic behavior of SMIs, this Perspective aims to lay the framework for both a better understanding of their inhibitive performance and strategies to innovate their design. It establishes two key interfaces—between the ALD precursor and the inhibitor, and between the inhibitor and the substrate—and discusses the role of each in selective deposition. Building upon the established understanding of SAMs together with current knowledge of SMIs, this Perspective aims to define guiding principles and key considerations for improving SMI design.